Form 4: Cytek Biosciences Director Don M. Hardison Acquires Stock Options and Restricted Stock Units

Director Don M. Hardison acquired stock options and restricted stock units in Cytek Biosciences, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Don M. Hardison, a director of Cytek Biosciences, Inc., acquired 23,076 stock options with an exercise price of $5.73, expiring between June 5, 2025, and June 5, 2034.
• Hardison also acquired 15,706 restricted stock units (RSUs), each representing a contingent right to receive one share of Cytek Biosciences common stock.
• The RSUs will vest 100% on June 5, 2025.
• Following these transactions, Hardison directly owns 23,076 stock options and 15,706 RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of insider transactions. The acquisition of shares could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of stock options and RSUs by a director may indicate confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates